SG11201401605QA - Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof - Google Patents
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereofInfo
- Publication number
- SG11201401605QA SG11201401605QA SG11201401605QA SG11201401605QA SG11201401605QA SG 11201401605Q A SG11201401605Q A SG 11201401605QA SG 11201401605Q A SG11201401605Q A SG 11201401605QA SG 11201401605Q A SG11201401605Q A SG 11201401605QA SG 11201401605Q A SG11201401605Q A SG 11201401605QA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- alkaline phosphatase
- natriuretic peptide
- natriuretic
- Prior art date
Links
- 102000002260 Alkaline Phosphatase Human genes 0.000 title 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 title 1
- 108020001621 Natriuretic Peptide Proteins 0.000 title 1
- 102000004571 Natriuretic peptide Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000692 natriuretic peptide Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549047P | 2011-10-19 | 2011-10-19 | |
| US201261649717P | 2012-05-21 | 2012-05-21 | |
| PCT/US2012/039004 WO2013058833A1 (en) | 2011-10-19 | 2012-05-22 | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201401605QA true SG11201401605QA (en) | 2014-09-26 |
Family
ID=48141235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401605QA SG11201401605QA (en) | 2011-10-19 | 2012-05-22 | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP3488861B1 (en) |
| JP (1) | JP6118807B2 (en) |
| KR (1) | KR20140084201A (en) |
| CA (1) | CA2852874A1 (en) |
| ES (2) | ES2714406T3 (en) |
| HK (1) | HK1201446A1 (en) |
| SG (1) | SG11201401605QA (en) |
| WO (2) | WO2013058833A1 (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2348114T3 (en) | 2004-04-21 | 2019-08-30 | Alexion Pharmaceuticals, Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| EP2658979B1 (en) * | 2010-12-27 | 2018-02-14 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| MX389350B (en) | 2014-12-05 | 2025-03-19 | Alexion Pharma Inc | RECOMBINANT ALKALINE PHOSPHATASES AND THEIR USES FOR THE TREATMENT OF SEIZURES. |
| US10603361B2 (en) | 2015-01-28 | 2020-03-31 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| JP6693134B2 (en) * | 2015-02-02 | 2020-05-13 | 東ソー株式会社 | Antibody having linker sequence and assay method using the same |
| CA3255406A1 (en) | 2015-03-31 | 2025-07-03 | Sorriso Pharmaceuticals, Inc. | Tnf-alpha binding polypeptides |
| WO2016156466A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Peptide construct having a protease-cleavable linker |
| JP2018511346A (en) | 2015-03-31 | 2018-04-26 | ブイエイチスクエアード リミテッド | Polypeptide |
| JP6882256B2 (en) | 2015-07-30 | 2021-06-02 | バイオマリン ファーマシューティカル インコーポレイテッド | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
| KR102644116B1 (en) * | 2015-08-17 | 2024-03-05 | 알렉시온 파마슈티칼스, 인코포레이티드 | Preparation of alkaline phosphatase |
| WO2017058822A1 (en) * | 2015-09-28 | 2017-04-06 | Alexion Pharmaceuticals, Inc. | Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia |
| JP2018533571A (en) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Methods for treating cranial suture early healing disease in a patient |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING HYPOPHOSPHATASIA IN ADOLESCENTS AND ADULTS |
| CA3019726A1 (en) * | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Treating muscle weakness with alkaline phosphatases |
| KR102646323B1 (en) * | 2016-05-06 | 2024-03-13 | 이뮤노포지 주식회사 | Elp fusion proteins for controlled and sustained release |
| EP3464573A4 (en) | 2016-06-06 | 2020-02-19 | Alexion Pharmaceuticals, Inc. | IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES |
| WO2018035420A1 (en) * | 2016-08-18 | 2018-02-22 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
| WO2018060453A1 (en) | 2016-09-30 | 2018-04-05 | Vhsquared Limited | Compositions |
| TWI856437B (en) | 2017-01-20 | 2024-09-21 | 法商賽諾菲公司 | Anti-tgf-beta antibodies and their use |
| TW202421659A (en) * | 2017-01-20 | 2024-06-01 | 美商健臻公司 | Bone-targeting antibodies |
| JP2020512363A (en) | 2017-03-31 | 2020-04-23 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Methods for treating hypophosphatasia (HPP) in adults and adolescents |
| EP3737750B1 (en) | 2018-01-09 | 2024-06-05 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
| US11638699B2 (en) | 2018-03-20 | 2023-05-02 | Theriva Biologics, Inc. | Intestinal alkaline phosphatase formulations |
| WO2019183209A1 (en) | 2018-03-20 | 2019-09-26 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| KR20220005560A (en) | 2019-05-06 | 2022-01-13 | 신세틱 바이오로직스, 인코퍼레이티드 | Alkaline Phosphate-Based Oncology Therapeutics |
| JP7680377B2 (en) | 2019-06-21 | 2025-05-20 | ソリッソ ファーマシューティカルズ，インク． | Polypeptides |
| CN114466864B (en) | 2019-06-21 | 2024-12-27 | 索瑞索制药公司 | Peptides |
| JP2023504208A (en) * | 2019-12-09 | 2023-02-01 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Alkaline phosphatase polypeptides and methods of use thereof |
| CA3190513A1 (en) * | 2020-09-03 | 2022-03-10 | Jeffrey S. Bartlett | Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs |
| US12083169B2 (en) | 2021-02-12 | 2024-09-10 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| CN119256089A (en) * | 2022-03-11 | 2025-01-03 | 阿维麦克思生物制药公司 | Compositions and methods for expressing therapeutic agents |
| KR20250150662A (en) | 2022-11-02 | 2025-10-20 | 노보 노르디스크 에이/에스 | Cnp compounds |
| CN116286763B (en) * | 2023-02-28 | 2024-06-25 | 西北工业大学 | Cystathionine beta-synthetase mutant with improved thermal stability and application |
| TW202513806A (en) * | 2023-06-07 | 2025-04-01 | 美商拜奧馬林製藥公司 | High throughput screen for genentic variants associated with short stature |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69108830T2 (en) | 1990-04-20 | 1995-09-14 | Hisayuki Matsuo | NEW PHYSIOLOGICALLY ACTIVE PEPTIDES IN PIGS. |
| JP3026351B2 (en) | 1990-07-13 | 2000-03-27 | 壽之 松尾 | Porcine CNP gene and precursor protein |
| JP2930380B2 (en) | 1990-07-13 | 1999-08-03 | 壽之 松尾 | New bioactive peptide derived from pig (CNP-53) |
| JP3026354B2 (en) | 1990-09-27 | 2000-03-27 | 壽之 松尾 | Human CNP gene and precursor protein |
| US5626863A (en) | 1992-02-28 | 1997-05-06 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| JP2809533B2 (en) | 1991-01-31 | 1998-10-08 | 壽之 松尾 | CNP analog peptide |
| WO1994020534A1 (en) | 1993-03-03 | 1994-09-15 | Mayo Foundation For Medical Education And Research | Vasonatrin peptide and analogs thereof |
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| WO2001036620A2 (en) | 1999-11-16 | 2001-05-25 | Genzyme Corporation | Vectors and transgenies with regulatory elements for gene delivery to the liver |
| US6407211B1 (en) | 1999-12-17 | 2002-06-18 | Mayo Foundation For Medical Education And Research | Chimeric natriuretic peptides |
| JP2002178279A (en) | 2000-12-12 | 2002-06-25 | Ulvac Japan Ltd | Substrate carrier method |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| DE60233047D1 (en) | 2001-05-14 | 2009-09-03 | Gbp Ip Llc | LENTIVIRAL VECTORS ENCODING FLAMMABLE FACTORS FOR GENETHERAPY |
| BRPI0203172B8 (en) | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | pharmaceutical composition for achondroplasia |
| HU230364B1 (en) | 2001-11-21 | 2016-03-29 | The Trustees Of The University Of Pennsylvania | Simian adeniovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| CA2433479A1 (en) | 2002-07-22 | 2004-01-22 | F. Hoffmann-La Roche Ag | Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof |
| DE60331584D1 (en) | 2002-11-26 | 2010-04-15 | Biocon Ltd | MODIFIED NATRIURETIC COMPOUNDS, CONJUGATES, AND ITS USES |
| EP1635872A4 (en) | 2003-05-30 | 2008-01-02 | Alexion Pharma Inc | Antibodies and fusion proteins that include engineered constant regions |
| JP4825667B2 (en) | 2004-03-31 | 2011-11-30 | 一和 中尾 | Joint inflammation treatment or prevention agent |
| EP3620530A1 (en) | 2004-03-31 | 2020-03-11 | Kazuwa Nakao | Composition for increasing body height |
| JP2005292718A (en) | 2004-04-05 | 2005-10-20 | Furukawa Electric Co Ltd:The | Optical waveguide, optical waveguide module, and method for producing optical waveguide |
| PL2348114T3 (en) | 2004-04-21 | 2019-08-30 | Alexion Pharmaceuticals, Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
| JP2008521575A (en) | 2004-12-01 | 2008-06-26 | ジェンザイム・コーポレイション | Delivery method of genetic material targeting the liver |
| US8043829B2 (en) * | 2006-10-25 | 2011-10-25 | Amgen Inc. | DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression |
| US20080181903A1 (en) | 2006-12-21 | 2008-07-31 | Pdl Biopharma, Inc. | Conjugate of natriuretic peptide and antibody constant region |
| PT2662448T (en) * | 2007-05-11 | 2017-03-29 | Alexion Pharma Inc | PHOSPHATASE ALKALINE DIRECTED TO THE BONE, KITS AND METHODS FOR THE USE OF THE SAME |
| EP2162464A1 (en) | 2007-06-06 | 2010-03-17 | Boehringer Ingelheim International GmbH | Natriuretic fusion proteins |
| DK2171053T3 (en) | 2007-07-20 | 2014-07-28 | Mayo Foundation | Natriuretic polypeptides |
| WO2009033807A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43 |
| AR069409A1 (en) | 2007-11-21 | 2010-01-20 | Biomarin Pharm Inc | VARIANTS OF NATURAL PEPTIDES OF TYPE C |
| HRP20220057T1 (en) | 2009-05-20 | 2022-04-15 | Biomarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
-
2012
- 2012-05-22 WO PCT/US2012/039004 patent/WO2013058833A1/en not_active Ceased
- 2012-05-22 CA CA2852874A patent/CA2852874A1/en not_active Abandoned
- 2012-05-22 SG SG11201401605QA patent/SG11201401605QA/en unknown
- 2012-05-22 KR KR1020147013214A patent/KR20140084201A/en not_active Withdrawn
- 2012-10-18 ES ES12842640T patent/ES2714406T3/en active Active
- 2012-10-18 WO PCT/US2012/060869 patent/WO2013059491A1/en not_active Ceased
- 2012-10-18 JP JP2014537254A patent/JP6118807B2/en active Active
- 2012-10-18 EP EP18201378.9A patent/EP3488861B1/en active Active
- 2012-10-18 EP EP12842640.0A patent/EP2768526B1/en active Active
- 2012-10-18 HK HK15101938.6A patent/HK1201446A1/en unknown
- 2012-10-18 ES ES18201378T patent/ES2944087T3/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2768526B1 (en) | 2018-12-05 |
| JP2015502336A (en) | 2015-01-22 |
| WO2013059491A1 (en) | 2013-04-25 |
| CA2852874A1 (en) | 2013-04-25 |
| ES2944087T3 (en) | 2023-06-19 |
| JP6118807B2 (en) | 2017-04-19 |
| EP3488861A1 (en) | 2019-05-29 |
| WO2013058833A1 (en) | 2013-04-25 |
| EP3488861B1 (en) | 2023-02-15 |
| KR20140084201A (en) | 2014-07-04 |
| HK1201446A1 (en) | 2015-09-04 |
| WO2013058833A8 (en) | 2013-06-13 |
| EP2768526A1 (en) | 2014-08-27 |
| ES2714406T3 (en) | 2019-05-28 |
| EP2768526A4 (en) | 2015-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201401605QA (en) | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof | |
| HUS2200031I1 (en) | Anti-cgrp compositions and use thereof | |
| EP2675471A4 (en) | Hsa-related compositions and methods of use | |
| ZA201406250B (en) | Compositions of glp-1 peptides and preparation thereof | |
| IL232977B (en) | Intranasal dexmedetomidine compositions and methods of use thereof | |
| PL2771071T3 (en) | Perfuming compositions and uses thereof | |
| HUE041627T2 (en) | Cleaning compositions and methods | |
| EP2668044A4 (en) | Compositions and their use | |
| EP2750697A4 (en) | Chimeric natriuretic peptide compositions and methods of preparation | |
| EP2741762A4 (en) | Natriuretic peptide compositions and methods of preparation | |
| ZA201300041B (en) | Methods and compositions of beneficiation | |
| IL234228B (en) | Compositions of glp-1 peptides and preparation thereof | |
| HK1191055A (en) | Compositions comprising natriuretic peptides and methods of use thereof | |
| GB201120470D0 (en) | Compositions and uses thereof |